Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Select Drug Profiles
,
Payers' Guide
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
,
FDA Approvals
,
Drug Updates
,
Payers' Guide
Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016
Dalia Buffery, MA, ABD
Read More
Select Drug Profiles
,
Payers' Guide
Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
11
12
13
14
15
16
17
Page 14 of 19
Results 131 - 140 of 185